X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare STRIDES PHARMA SCIENCE with Biocon Ltd - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

STRIDES PHARMA SCIENCE vs BIOCON LTD - Comparison Results

STRIDES PHARMA SCIENCE    Change

Strides Arcolab is an Indian pharmaceutical company headquartered at Bangalore. The company is primarily involved in two businesses notably the pharma business and the specialized sterile products business branded as Agila. This segment focuses large... More

BIOCON LTD 
   Change

Biocon is India's largest biotechnology company with presence in biopharmaceuticals, custom research and clinical research. It started as an enzymes manufacturer and later evolved into an integrated biopharmaceutical company. The company has two subs... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    STRIDES PHARMA SCIENCE BIOCON LTD STRIDES PHARMA SCIENCE/
BIOCON LTD
 
P/E (TTM) x 52.2 50.3 103.6% View Chart
P/BV x 1.1 7.3 15.5% View Chart
Dividend Yield % 0.4 0.2 270.9%  

Financials

 STRIDES PHARMA SCIENCE   BIOCON LTD
EQUITY SHARE DATA
    STRIDES PHARMA SCIENCE
Mar-18
BIOCON LTD
Mar-18
STRIDES PHARMA SCIENCE/
BIOCON LTD
5-Yr Chart
Click to enlarge
High Rs1,1471,188 96.5%   
Low Rs642305 210.5%   
Sales per share (Unadj.) Rs317.268.7 461.6%  
Earnings per share (Unadj.) Rs7.87.6 103.9%  
Cash flow per share (Unadj.) Rs25.114.0 179.4%  
Dividends per share (Unadj.) Rs2.001.00 200.0%  
Dividend yield (eoy) %0.20.1 166.9%  
Book value per share (Unadj.) Rs274.386.3 317.6%  
Shares outstanding (eoy) m89.50600.00 14.9%   
Bonus/Rights/Conversions ESOPIS-  
Price / Sales ratio x2.810.9 26.0%   
Avg P/E ratio x114.098.9 115.3%  
P/CF ratio (eoy) x35.753.4 66.8%  
Price / Book Value ratio x3.38.6 37.7%  
Dividend payout %25.513.2 192.5%   
Avg Mkt Cap Rs m80,058447,900 17.9%   
No. of employees `0002.56.1 40.8%   
Total wages/salary Rs m4,3419,311 46.6%   
Avg. sales/employee Rs Th11,325.86,705.8 168.9%   
Avg. wages/employee Rs Th1,731.41,514.2 114.3%   
Avg. net profit/employee Rs Th280.1736.9 38.0%   
INCOME DATA
Net Sales Rs m28,39441,234 68.9%  
Other income Rs m9412,062 45.6%   
Total revenues Rs m29,33443,296 67.8%   
Gross profit Rs m3,9658,291 47.8%  
Depreciation Rs m1,5403,851 40.0%   
Interest Rs m1,962615 319.1%   
Profit before tax Rs m1,4035,887 23.8%   
Minority Interest Rs m0213 0.0%   
Prior Period Items Rs m-1680-   
Extraordinary Inc (Exp) Rs m-4360-   
Tax Rs m971,569 6.2%   
Profit after tax Rs m7024,531 15.5%  
Gross profit margin %14.020.1 69.5%  
Effective tax rate %6.926.7 26.0%   
Net profit margin %2.511.0 22.5%  
BALANCE SHEET DATA
Current assets Rs m24,83641,486 59.9%   
Current liabilities Rs m18,99321,413 88.7%   
Net working cap to sales %20.648.7 42.3%  
Current ratio x1.31.9 67.5%  
Inventory Days Days7164 111.0%  
Debtors Days Days11394 120.4%  
Net fixed assets Rs m34,28950,661 67.7%   
Share capital Rs m8953,000 29.8%   
"Free" reserves Rs m23,65148,808 48.5%   
Net worth Rs m24,54651,808 47.4%   
Long term debt Rs m15,51317,898 86.7%   
Total assets Rs m65,43799,897 65.5%  
Interest coverage x1.710.6 16.2%   
Debt to equity ratio x0.60.3 182.9%  
Sales to assets ratio x0.40.4 105.1%   
Return on assets %4.15.2 79.0%  
Return on equity %2.98.7 32.7%  
Return on capital %6.99.6 71.6%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m15,69712,058 130.2%   
Fx outflow Rs m7357,348 10.0%   
Net fx Rs m14,9624,710 317.7%   
CASH FLOW
From Operations Rs m1,8716,621 28.3%  
From Investments Rs m5,826-6,840 -85.2%  
From Financial Activity Rs m-10,157-2,397 423.7%  
Net Cashflow Rs m-2,615-2,612 100.1%  

Share Holding

Indian Promoters % 27.7 40.4 68.6%  
Foreign collaborators % 0.0 20.6 -  
Indian inst/Mut Fund % 37.8 8.4 450.0%  
FIIs % 8.6 10.7 80.4%  
ADR/GDR % 0.0 0.0 -  
Free float % 25.9 19.9 130.2%  
Shareholders   56,241 109,995 51.1%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare STRIDES PHARMA SCIENCE With:   PIRAMAL ENTERPRISES  GSK PHARMA  DR. DATSONS LABS  DR. REDDYS LAB  NOVARTIS  

Compare STRIDES PHARMA SCIENCE With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 307 Points Higher; Metal and Oil & Gas Stocks Witness Buying(Closing)

Indian share markets traded on a positive note throughout the day and ended on a strong note. Gains were seen in the metal sector.

Related Views on News

BIOCON LTD Announces Quarterly Results (2QFY19); Net Profit Up 501.9% (Quarterly Result Update)

Nov 9, 2018 | Updated on Nov 9, 2018

For the quarter ended September 2018, BIOCON LTD has posted a net profit of Rs 4 bn (up 501.9% YoY). Sales on the other hand came in at Rs 13 bn (up 36.4% YoY). Read on for a complete analysis of BIOCON LTD's quarterly results.

STRIDES PHARMA SCIENCE Announces Quarterly Results (2QFY19); Net Profit Down 72.2% (Quarterly Result Update)

Nov 6, 2018 | Updated on Nov 6, 2018

For the quarter ended September 2018, STRIDES PHARMA SCIENCE has posted a net profit of Rs 54 m (down 72.2% YoY). Sales on the other hand came in at Rs 7 bn (down 26.4% YoY). Read on for a complete analysis of STRIDES PHARMA SCIENCE's quarterly results.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

More Views on News

Most Popular

It's Almost the Perfect Time to Buy This Safe Stock(The 5 Minute Wrapup)

Dec 6, 2018

My latest StockSelect recommendation ticks all the boxes of a great safe stock.

Patel's Exit, Election Results, and 4 'Must Have' Small Caps in These Exceptional Times(Profit Hunter)

Dec 11, 2018

RBI Governor's resignation is a statement of dissent with the way government is handling the economy's affairs and could lead to some serious market correction. Here's how to make the most of it.

Players in an Oligopoly Should Have Financials Like This(Chart Of The Day)

Dec 7, 2018

This stock has corrected 30% from peak and looks attractive at these valuations.

Looking For Higher Interest Rates on Bank FDs? Read This!(Outside View)

Dec 5, 2018

Credit disbursement to the productive sectors of the economy such as infrastructure, engineering, food processing, textiles, and chemicals, among others is rising.

DSP Mutual Fund's Sale of DHFL Bonds: Here's What You Need to Know(Outside View)

Dec 5, 2018

PersonalFN explains the probable reason as to why the capital market regulator has initiated DSP Mutual Fund's bond sale that caused DHFL stock to crash.

More

Small Investments
BIG Returns

Zero To Millions Guide 2019
Get our special report, Zero To Millions
(2019 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

STRIDES PHARMA SCIENCE SHARE PRICE


Dec 17, 2018 (Close)

TRACK STRIDES PHARMA SCIENCE

  • Track your investment in STRIDES PHARMA SCIENCE with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON STRIDES PHARMA SCIENCE

STRIDES PHARMA SCIENCE 5-YR ANALYSIS

COMPARE STRIDES PHARMA SCIENCE WITH

MARKET STATS